To Determine if Olanzapine is More Cost Effective Than Haloperidol for the Treatment of Schizophrenia
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Although currently marketed antipsychotic drugs are useful in the treatment of schizophrenia,
efficacy and safety profiles need to be improved. Forty to eighty percent of patients either
fail to respond or only partially respond to conventional antipsychotic agents. Secondary
symptoms may be unimproved even in patients who respond to treatment. A variety of adverse
events occur in patients receiving currently available agents. The severity of these events
contributes to the poor compliance that is observed in this patient population. Olanzapine is
a novel antipsychotic agent with a reduced incidence of extrapyramidal symptoms. Other side
effects are minimal.
Phase:
Phase 4
Details
Lead Sponsor:
US Department of Veterans Affairs VA Office of Research and Development